Grandmother dies from rabies after ‘very slight scratch' from puppy in Morocco
The family of a grandmother who died after contracting rabies said she was scratched 'very slightly' by a puppy while visiting Morocco in February.
Yvonne Ford's family said she only became ill two weeks ago, starting with a headache and resulting in her becoming unable to walk, talk, sleep or swallow.
Ms Ford, from Barnsley, South Yorkshire, died in Sheffield on June 11 aged 59, according to Sheffield Coroner's Court, where an inquest was opened and adjourned on Wednesday morning.
Barnsley Hospital NHS Foundation Trust confirmed she was diagnosed with rabies at Barnsley Hospital.
A Facebook post which her daughter Robyn Thomson made to raise awareness said: 'Our family is still processing this unimaginable loss, but we are choosing to speak up in the hope of preventing this from happening to others.
'Yvonne Ford, Ron Ford's wife and our Mum, died of rabies.
'She was scratched very slightly by a puppy in Morocco in February.
'At the time, she did not think any harm would come of it and didn't think much of it.
'Two weeks ago she became ill, starting with a headache and resulted in her losing her ability to walk, talk, sleep, swallow.
'Resulting in her passing.'
Ms Thomson shared information about rabies, including that it is preventable through prompt medical care after exposure.
She added: 'We never thought something like this could happen to someone we love. Please take animal bites seriously, vaccinate your pets, and educate those around you.'
The UK Health Security Agency (UKHSA) said there is no risk to the wider public because there is no evidence rabies can be passed between people.
However, as a precautionary measure it is assessing health workers and close contacts to offer vaccination where necessary.
Rabies is a deadly virus spread through the saliva of infected animals, and people usually get it after being bitten by an infected animal.
Animals such as cows, cats and foxes can carry the virus but, in developing countries, stray dogs are the most likely to spread rabies to people.
Once a person begins showing signs and symptoms of rabies, the disease is nearly always fatal.
The first symptoms of rabies can be similar to flu, while later symptoms include fever, headache, nausea, vomiting, agitation, anxiety, difficulty swallowing and excessive saliva.
People may develop fears around things like swallowing drinks and can suffer hallucinations and paralysis.
Dr Katherine Russell, Head of Emerging Infections and Zoonoses, at the UKHSA, said: 'I would like to extend my condolences to this individual's family at this time.
'If you are bitten, scratched or licked by an animal in a country where rabies is found then you should wash the wound or site of exposure with plenty of soap and water and seek medical advice without delay in order to get post-exposure treatment to prevent rabies.
'There is no risk to the wider public in relation to this case.
'Human cases of rabies are extremely rare in the UK, and worldwide there are no documented instances of direct human-to-human transmission.'
According to the UKHSA, rabies does not circulate in either wild or domestic animals in the UK, although some species of bats can carry a rabies-like virus.
There have been no human cases of rabies acquired in the UK from animals other than bats reported since 1902.
Between 2000 and 2024, there were six cases of rabies reported in the UK linked to people being exposed abroad.
Rabies is common in other parts of the world, especially Asia and Africa.
Travellers are being advised by the UKHSA to avoid contact with dogs, cats and other animals and check whether they may need a rabies vaccine prior to travel.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Father-of-four dies of bowel cancer, aged 40, within months of being diagnosed - the only warning sign was terrifyingly easy to dismiss
A father-of-four whose only sign of deadly bowel cancer was a troubling stomach ache has died, eight months after being told he had the disease. Kyle Ingram-Baldwin, 40, had only just launched a fundraiser on June 8 to pay for alternative treatments as he was 'not prepared to give up'. But in a heartbreaking post on the funding platform his wife Becky confirmed he had died on June 16. 'Unfortunately, Kyle took a very sudden and unexpected turn and we lost him yesterday,' she wrote. 'He was the most incredible man I have ever met, and I know he would want me to thank everyone for all your sharing and donations.' His death comes amid a worrying trend of younger adults being diagnosed with the devastating disease. Mr Ingram-Baldwin, from Minster, Kent, originally sought help from his GP in October after suffering a persistent stomach ache that he suspected was linked to stress or gallstones. But after the pain got worse he ended up attending A&E where scans revealed the true devastating cause. An ultrasound showed worrying bulges on his liver, with a follow-up CT scan confirming these were cancer. Further tests revealed these were secondary growths from a cancer that had originated in his bowel. This meant the disease was already at stage-four, the final and most serious stage. Only 10 per cent of bowel cancer patients diagnosed at stage four are alive five years later, according to Cancer Research UK. Recalling the moment he got the news Mr Ingram-Baldwin said the mental toll was extraordinary. 'I was thinking, what's going on here? What have I done wrong? I was putting the blame on my own feet and worrying about the future for my wife and kids,' he said. 'That's probably the hardest thing-the mental side. 'Don't get me wrong, the physical is not funny either, but it's a mental challenge.' Mr Ingram-Baldwin, who worked for a vending machine supplier, underwent more than half-a-dozen rounds of gruelling chemotherapy. But, unfortunately, this failed to bring the disease under control. Shortly before his death Mr Ingram-Baldwin spoke about how the cancer had impacted his wife, and children aged 12, nine, three and one. 'It's really hard to put into words, because I love my kids so much. You just worry about their future,' he said. 'They've got the best mum in the world, and I genuinely mean that. My wife's incredible.' He urged other patients to not dismiss signs that something isn't right in their bodies. 'I didn't present with any of the conventional symptoms,' he said. 'If you think anything's wrong, please press your GP and go get it checked, because I genuinely wouldn't want anyone being in my position.' Symptoms of the bowel cancer include changes in bowel movements such as diarrhoea or constipation, needing or feeling the need to empty your bowels more or less frequently, blood in stool, stomach pain, bloating, as well as unexpected weight loss and fatigue. Stomach pain like Mr Ingram-Baldwin experienced, a lump in the stomach, bloating and fatigue are also among other common signs. Mr Ingram-Baldwin isn't alone in being hit by a devastating bowel cancer diagnosis as a young adult. Experts have noted a concerning and mysterious rise in rates of the disease among young adults, defined in cancer terms as those under 50. A recent global study found rates of bowel cancer in under 50 year-olds are rising in 27 of 50 nations. England is averaging a 3.6 per cent rise in younger adults every year-one of the highest increases recorded. While the disease is known linked to obesity, experts have noted that the disease also seems to also be occurring in fit and healthy patients. Some experts believe the explanation must lie in environmental factors young people have been exposed to more than previous generations. While no 'smoking gun' has been found, there are multiple theories. These include modern chemicals in diets, microplastics, pollution, and one recent study even pinned the surge on exposure to in food. There are around 2,600 new bowel cancer cases in people aged 25-49 in Britain every year, and around 44,100 new cases among all ages. Around 44,000 cases of bowel cancer are diagnosed every year in the UK, with about 130,000 in the US. The disease kills almost 17,000 Britons each year, with the death toll rising to about 50,000 in America. Overall, just over half of bowel cancer patients are expected to be alive 10 years after their diagnosis. More than £15,000 was raised in Mr Ingram-Baldwin's drive for alternative treatments. Mrs Ingram-Baldwin has now confirmed the amount would now be re-funded to donors. She urged people to consider donating the money to charity or using it to 'make memories with your families'.
Daily Mail
3 hours ago
- Daily Mail
Senior NHS nurse who was told to remove 'anti-Semitic fruit bowl' from video call background launches legal action
A British-Palestinian NHS nurse who says he was told to remove a background on his video calls because it could be perceived as 'anti Semitic' has launched legal action against his employer. Ahmad Baker, a senior nurse, claims hospital bosses complained about the image of a fruit bowl containing watermelons - which have been adopted as a symbol of Palestine. Barts Health NHS trust, which runs Whipps Cross hospital in north London where Mr Baker works, has banned staff from displaying symbols seen as politically or nationally affiliated. The ban was introduced in March this year and applies to uniform, workstations, laptops and iPads. However, Mr Baker and two other members of staff have argued that the measures are disproportionate and discriminatory to those with pro-Palestinian beliefs. He claims he was threatened with disciplinary action for displaying the watermelon symbols on his wallpaper as they could be seen as 'anti Semitic'. Mr Baker told The Guardian: 'As a Palestinian, I should be able to express my identity and solidarity with my people, especially during a humanitarian crisis. 'Being told that a still-life painting containing a watermelon could be perceived as antisemitic and being threatened with disciplinary action is deeply upsetting. 'I've worked for the NHS for over a decade – this is not the inclusivity I thought we stood for.' Mr Baker has launched the legal action alongside other trust employees Dr Aarash Saleh, a respiratory consultant at Whipps Cross, and Dr Sara Ali, a haematology registrar. The group is arguing that the policy amounts to indirect discrimination under the Equality Act 2010 and is disproportionate to those with pro-Palestinian beliefs. They have also pointed to the fact that Barts Health NHS trust has openly supported Ukraine amid the ongoing conflict with Russia. The group have started a CrowdJustice page to help them raise money to fight the case. More than £16,000 has already been raised of a £50,000 target. On the page they wrote: This legal case is about how senior executives at Barts Health NHS Trust have imposed a new uniform policy to ban any visible expressions of support for Palestinians as they suffer unprecedented potentially amounting to a genocide. 'Barts Health's decision has followed direct pressure from UK Lawyers for Israel (UKLFI), a pro-Israel lobby group. 'Please support us in opposing this discriminatory policy which contravenes NHS core values and basic rights of expression.' A spokesperson for Barts Health NHS trust said: 'We recognise the distress that global conflict has for our diverse workforce and continue to support their wellbeing as they serve our patients. 'However, as an NHS organisation our primary responsibility is care for patients.'
BBC News
4 hours ago
- BBC News
Breakthrough Alzheimer's drugs too pricey to be offered on NHS
Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the medicines are the first to slow the disease, which may give people extra time living National Institute for Health and Care Excellence (NICE) concluded they were a poor use of taxpayers' money and said funding them could lead to other services being say it is a disappointment, but dementia experts have also supported the decision. The two drugs, donanemab and lecanemab, both help the body clear a gungy protein that builds up in the brains of people with Alzheimer's medicines do not reverse or even stop the disease, rather brain power is lost more slowly with trials of these drugs were celebrated as a scientific triumph as they showed, for the first time, it was possible to change the course of Alzheimer' since then a row has developed over the cost of the drugs and how meaningful the benefit is. The official price in the US is £20,000-£25,000 per patient per year. What the NHS would pay is 70,000 people in England with mild dementia would have been eligible, potentially putting the bill in the region of £1.5bn a year for the drugs resources, including regularly infusing the drugs directly into spinal fluid and frequent brain scans to manage dangerous side effects, would also massively ramp up the cost. The benefit of the drugs is also debated. They potentially delay the transition from mild to moderate dementia by four-to-six months. That could mean more time without needing daily care, driving, being present for significant family events and Prof Rob Howard, from University College London, said real-world benefits "were too small to be noticeable". In trials of lecanemab, patients were better off by 0.45 points, on an 18-point scale ranging from healthy to severe he said the cost would "have been close to the cost of a nurse's salary for each treated patient".The decision not to fund the drugs is not a surprise. The first assessment last year concluded they were not Knight, director of medicines evaluation at NICE, acknowledged the latest news would be "disappointing" but said the benefits were "modest" at best while requiring "substantial resources"."If they were approved they could displace other essential treatments and services that deliver significant benefits to patients," she said. NICE said its appraisal had factored in potential savings in the cost of providing care, but the drugs were still deemed decisions apply to the NHS in England, but are normally adopted by Wales and Northern Ireland too. Scotland has its own method for approving pharmaceutical companies have three weeks to raise concerns about how the review was performed, otherwise the decision becomes final on 23 pharmaceutical companies involved, Eisai for lecanemab and Eli Lilly for donanemab, say they will appeal against the decision. Nick Burgin, from Eisai said the NHS "is not ready" for the challenge of tackling Alzheimer's and flaws in the process meant their drug would have been rejected "even if Eisai provided lecanemab to the NHS for free".Eli Lilly, the company behind donanemab, has already expressed its disappointment. "If the system can't deliver scientific firsts to NHS patients, it is broken," said Chris Stokes, Eli Lilly's president and general manager of UK and Northern Europe. Is this a distraction or a disappointment? The sentiment was echoed by both the Alzheimer's charities. Prof Fiona Carragher, from the Alzheimer's Society said "the science is flying but the system is failing" and it was "highly disappointing" the drugs were not available on the Evans-Newton, the chief executive at Alzheimer's Research UK, said the result was "painful" and patients will miss out on this and future innovations "not because science is failing, but because the system is".However, others say NICE has made the right call. Tom Dening, professor of dementia research at the University of Nottingham, said he was "in complete support" as the benefits of the drugs were "minimal" and a "distraction" from the real issues in dementia."[Namely the] unglamorous challenge of providing people with dementia and their families with activities, care and support that we already know are beneficial for their mental and physical health," he Atticus Hainsworth, from St George's, University of London, said: "NICE is simply doing its job."Beyond lecanemab and donenamab there are 138 dementia medicines being tested in 182 trials around the Tara Spires-Jones, director of the centre for discovery brain sciences at the University of Edinburgh, said: "There is hope for safer, more effective treatments on the horizon."
